AZ Crows About Oncology Portfolio In 1Q; Strives For $1.1bn Cost Save
AstraZeneca PLC is restructuring and streamlining its commercial and manufacturing operations under a new cost-cutting effort in order to save $1.1bn annually from 2017 and focus internally on just three core areas.
You may also be interested in...
The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.